392 related articles for article (PubMed ID: 27177084)
41. Downregulation of STAT3/NF-κB potentiates gemcitabine activity in pancreatic cancer cells.
Gong J; Muñoz AR; Pingali S; Payton-Stewart F; Chan DE; Freeman JW; Ghosh R; Kumar AP
Mol Carcinog; 2017 Feb; 56(2):402-411. PubMed ID: 27208550
[TBL] [Abstract][Full Text] [Related]
42. Mucin production determines sensitivity to bortezomib and gemcitabine in pancreatic cancer cells.
Wissniowski TT; Meister S; Hahn EG; Kalden JR; Voll R; Ocker M
Int J Oncol; 2012 May; 40(5):1581-9. PubMed ID: 22266985
[TBL] [Abstract][Full Text] [Related]
43. MicroRNA-29c Increases the Chemosensitivity of Pancreatic Cancer Cells by Inhibiting USP22 Mediated Autophagy.
Huang L; Hu C; Cao H; Wu X; Wang R; Lu H; Li H; Chen H
Cell Physiol Biochem; 2018; 47(2):747-758. PubMed ID: 29807360
[TBL] [Abstract][Full Text] [Related]
44. TIMP1 down-regulation enhances gemcitabine sensitivity and reverses chemoresistance in pancreatic cancer.
Tan Y; Li X; Tian Z; Chen S; Zou J; Lian G; Chen S; Huang K; Chen Y
Biochem Pharmacol; 2021 Jul; 189():114085. PubMed ID: 32522594
[TBL] [Abstract][Full Text] [Related]
45. The mitochondrion interfering compound NPC-26 exerts potent anti-pancreatic cancer cell activity in vitro and in vivo.
Dong YY; Zhuang YH; Cai WJ; Liu Y; Zou WB
Tumour Biol; 2016 Nov; 37(11):15053-15063. PubMed ID: 27658776
[TBL] [Abstract][Full Text] [Related]
46. [An experimental study of gemcitabine inducing pancreatic cancer cell apoptosis potentiated by nuclear factor-kappa B P65 siRNA].
Kong R; Sun B; Wang SJ; Pan SH; Wang G; Chen H; Xue DB; Jiang HC
Zhonghua Wai Ke Za Zhi; 2010 Jan; 48(2):128-33. PubMed ID: 20302733
[TBL] [Abstract][Full Text] [Related]
47. BMI1 activates P-glycoprotein via transcription repression of
Chen MK; Zhou JH; Wang P; Ye YL; Liu Y; Zhou JW; Chen ZJ; Yang JK; Liao DY; Liang ZJ; Xie X; Zhou QZ; Xue KY; Guo WB; Xia M; Bao JM; Yang C; Duan HF; Wang HY; Huang ZP; Qin ZK; Liu CD
Aging (Albany NY); 2021 Jul; 13(14):18310-18330. PubMed ID: 34270461
[TBL] [Abstract][Full Text] [Related]
48. Gemcitabine resistance induced by interaction between alternatively spliced segment of tenascin-C and annexin A2 in pancreatic cancer cells.
Gong XG; Lv YF; Li XQ; Xu FG; Ma QY
Biol Pharm Bull; 2010; 33(8):1261-7. PubMed ID: 20686216
[TBL] [Abstract][Full Text] [Related]
49. Mucin 5AC Serves as the Nexus for β-Catenin/c-Myc Interplay to Promote Glutamine Dependency During Pancreatic Cancer Chemoresistance.
Ganguly K; Bhatia R; Rauth S; Kisling A; Atri P; Thompson C; Vengoji R; Ram Krishn S; Shinde D; Thomas V; Kaur S; Mallya K; Cox JL; Kumar S; Batra SK
Gastroenterology; 2022 Jan; 162(1):253-268.e13. PubMed ID: 34534538
[TBL] [Abstract][Full Text] [Related]
50. Identification of NME5 as a contributor to innate resistance to gemcitabine in pancreatic cancer cells.
Li F; Hu G; Jiang Z; Guo J; Wang K; Ouyang K; Wen D; Zhu M; Liang J; Qin X; Zhang L
FEBS J; 2012 Apr; 279(7):1261-73. PubMed ID: 22325559
[TBL] [Abstract][Full Text] [Related]
51. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signaling.
Liu J; Ma J; Wu Z; Li W; Zhang D; Han L; Wang F; Reindl KM; Wu E; Ma Q
BMC Cancer; 2014 Sep; 14():686. PubMed ID: 25240403
[TBL] [Abstract][Full Text] [Related]
52. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
[TBL] [Abstract][Full Text] [Related]
53. Enhanced effect of gemcitabine by emodin against pancreatic cancer in vivo via cytochrome C-regulated apoptosis.
Chen H; Wei W; Guo Y; Liu A; Tong H; Wang Z; Tan W; Liu J; Lin S
Oncol Rep; 2011 May; 25(5):1253-61. PubMed ID: 21305255
[TBL] [Abstract][Full Text] [Related]
54. NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-κB activation.
Zhuang Z; Li H; Lee H; Aguilar M; Gocho T; Ju H; Iida T; Ling J; Fu J; Wu M; Sun Y; Lu Y; Chiao PJ
Cancer Lett; 2017 Dec; 411():44-56. PubMed ID: 28951128
[TBL] [Abstract][Full Text] [Related]
55. Combination chemotherapy of nafamostat mesylate with gemcitabine for gallbladder cancer targeting nuclear factor-κB activation.
Iwase R; Haruki K; Fujiwara Y; Furukawa K; Shiba H; Uwagawa T; Misawa T; Ohashi T; Yanaga K
J Surg Res; 2013 Sep; 184(1):605-12. PubMed ID: 23830367
[TBL] [Abstract][Full Text] [Related]
56. Hexokinase 2 dimerization and interaction with voltage-dependent anion channel promoted resistance to cell apoptosis induced by gemcitabine in pancreatic cancer.
Fan K; Fan Z; Cheng H; Huang Q; Yang C; Jin K; Luo G; Yu X; Liu C
Cancer Med; 2019 Oct; 8(13):5903-5915. PubMed ID: 31426130
[TBL] [Abstract][Full Text] [Related]
57. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T
Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057
[TBL] [Abstract][Full Text] [Related]
58. Rab14 overexpression regulates gemcitabine sensitivity through regulation of Bcl-2 and mitochondrial function in pancreatic cancer.
Ge J; Ge C
Virchows Arch; 2019 Jan; 474(1):59-69. PubMed ID: 30267303
[TBL] [Abstract][Full Text] [Related]
59. Nuclear factor-kappaB p65/relA silencing induces apoptosis and increases gemcitabine effectiveness in a subset of pancreatic cancer cells.
Pan X; Arumugam T; Yamamoto T; Levin PA; Ramachandran V; Ji B; Lopez-Berestein G; Vivas-Mejia PE; Sood AK; McConkey DJ; Logsdon CD
Clin Cancer Res; 2008 Dec; 14(24):8143-51. PubMed ID: 19088029
[TBL] [Abstract][Full Text] [Related]
60. Ginkgolide B enhances gemcitabine sensitivity in pancreatic cancer cell lines via inhibiting PAFR/NF-кB pathway.
Lou C; Lu H; Ma Z; Liu C; Zhang Y
Biomed Pharmacother; 2019 Jan; 109():563-572. PubMed ID: 30399592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]